Spotlight on the pharmacoeconomics of escitalopram in depression

CNS Drugs

Volumn 18, Issue 7, 2004, Pages 469-473

  Croom, Katherine F ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANOREXIA; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING;

CITALOPRAM; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEPRESSION; ECONOMICS, PHARMACEUTICAL; EUROPE; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 2942542974     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418070-00005     Document Type: Review

References (46)

1. Kessler RC, Berglund P, Demier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun; 289 (23): 3095-105
2. Lépine J-P, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997 Jan; 12 (1): 19-29
3. Angst J. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry 1996; 168 Suppl. 30: 31-7
4. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276 (4): 293-9
5. Ayuso-Mateos JL, Vazquez-Barquero JL, Dowrick C, et al. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry 2001 Oct; 179: 308-16
6. Thase ME. Long-term nature of depression. J Clin Psychiatry 1999; 60 Suppl. 14: 3-9
7. Keller MB, Hirschfeld RMA, Demyttenaere K, et al. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol 2002 Nov; 17 (6): 265-71
8. Hirschfield RMA. Clinical importance of long-term antidepressant treatment. Br J Psychiatry 2001; 179 Suppl. 42: S4-8
9. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. 1997 May; 349 (9064): 1498-504
10. World Health Organization. The global burden of disease [online]. Available from URL: http://who.int/msa/mnh/ems/dalys/ table.htm [Accessed 2003 Jun 6]
11. Mody SH, Edell WS, Durkin MB, et al. The impact of depression on health-related quality of life [abstract no. PMH27]. Value Health 2000; 3 (2): 87
12. Patrick D, LIDO Group. Quality of life correlates of major depression in six countries [abstract no. S-224-4 plus oral presentation]. 12th World Congress of Psychiatry, 2002 Aug 24; Yokohama, 219
13. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD Study. JAMA 1995 Nov; 274 (19): 1511-7
14. Penninx BWJH, Geerlings SW, Deeg DJH, et al. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry 1999 Oct; 56 (10): 889-95
15. Zheng D, Macera CA, Croft JB, et al. Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol 1997 Apr; 7 (3): 213-8
16. Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999; 60 Suppl. 2: 57-62
17. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989 Aug 18; 262 (7): 914-9
18. Ohayon MM, Priest RG, Guilleminault C, et al. The prevalence of depressive disorders in the United Kingdom. Biol Psychiatry 1999 Feb; 45 (3): 300-7
19. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277 (4): 333-40
20. Donoghue J, Taylor DM. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000 May; 13 (5): 365-83
21. Berto P, D'Ilario D, Ruffo P, et al. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000 Mar 1; 3 (1): 3-10
22. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993 Jan; 7: 191-5
23. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov; 54 (11): 405-18
24. Kiejna A, Czech M, Faluta T, et al. Cost of the first, second and subsequent episode of depression in Poland [abstract]. Value Health 2001; 4 (6): 416
25. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost- effective antidepressant use. Part 1: Depression and its treatment. Pharmacoeconomics 1997 May; 11 (5): 419-43
26. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr; 63 (4): 331-6
27. Wade A, Lemming OM, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 May; 17 (3): 95-102
28. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 Jul; 18 (4): 211-7
29. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients [abstract]. Int J Psychiatry Clin Prac 2002; 6 (4): 243-4 plus poster presented at the 3rd International Forum on Mood and Anxiety Disorders; 2003 Nov 27-30; Monte Carlo
30. Montgomery SA, Huusom AKT, Bothmer J. Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder [abstract no. P. 1.206]. Eur Neuropsychopharmacol 2002; 12 Suppl. 3: S224
31. Ninan PT, Ventura, D, Wang, J. Escitalopram is effective and well-tolerated in the treatment of severe depression [abstract no. NR486 plus poster]. American Psychiatric Association Annual Meeting; 2003 May 17-23, San Francisco
32. Bielski R, Ventura D, Chang C, et al. Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder [abstract no. P. 1.207]. European Neuropsychopharmacol 2003; 13 Suppl. 4: S262 plus poster presented at the 16th Congress of the European College of Neuropsychopharmacology 2003 Sep 20-24, Prague
33. Wade A, Despiegel N, Reines E. Depression in primary care patients: improvement during long-term escitalopram treatment [abstract no. P.1.156]. Eur Neuropsychopharmacol 2002; 12 Suppl. 3: 232
34. Rapaport MH, Bose A, Zheng H. Escitalopram prevents relapse of depressive episodes [abstract no. P01.12]. Eur Psychiatry 2002; 17 Suppl. 1: 97
35. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7 Suppl. 1: 40-4
36. Auquier P, Robitail S, Llorca P-M, et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Prac. In press
37. Gergel I, Hakkarainen H, Zornberg G. Escitalopram is a well tolerated SSRI [abstract no. NR333]. American Psychiatric Association Annual Meeting; 2002 May 18-23, Philadelphia.
38. Wade A, Despiegel N, Glesner LE. Depression in primary care patients: escitalopram is safe and well tolerated in long-term treatment [abstract no. P.3.E.035]. Int J Neuropsychopharmacol 2002 Jun; 5 Suppl. 1: S146 plus poster presented at the 23rd ECNP Congress; 2002 Oct 5-9, Barcelona
39. H. Lundbeck A/S. Cipralex: summary of product characteristics [online]. Available from URL: http:www.cipralex.com [Accessed 2003 Jun 10]
40. Fernandez J, Montgomery SA, François C. Economic evaluation of the cost-effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Paris: Lundbeck A/S, 2003. (Data on file)
41. Montgomery SA, Fernandez JL, François C. Treatment of depression: escitalopram has similar efficacy but lower costs compared to venlafaxine XR [abstract no. PMH42]. Value Health 2003; 6(3): 358 plus poster presented at the ISPOR Eighth Annual Meeting; 2003 May 18-21; Arlington (VA)
42. François C, Toumi M, Aakhus A-M, et al. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Eur J Health Econom 2003; 4: 12-9
43. Demyttenaere K, Rachidi S, Van Dijck P, et al. Cost-effectiveness of escitalopram compared to brand and generic SSRI (citalopram and fluoxetine), and venlafaxine in the treatment of depression in Belgium. Paris: Lundbeck A/S, 2003. (Data on file)
44. Wade A, McCrone, P, Anderson I, et al. Cost-effectiveness of escitalopram, a new SSRI, in the treatment of major depressive disorder in the UK [abstract plus poster]. 1st Asia-Pacific Conference for Pharmacoeconomic and Outcomes Research; 2003 Sep 1-3, Kobe, Japan.
45. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91-107
46. Francois C, Henriksson F, Toumi M, et al. A Swedish pharmacoeconomic evaluation of escitalopram, a new SSRI: comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine and venlafaxine [abstract]. Value Health 2002; 5 (3): 230 plus poster prsented at the ISPOR Seventh Annual International Meeting; 2002 May 19-230 plus poster prsented at the ISPOR Seventh Annual International M22; Arlington (VA)